Joshua Zeidner, MD | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Joshua Zeidner, MD

Primary Disease Area of Focus: 
  • Acute Myeloid Leukemia (AML)
  • Aplastic Anemia
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Neoplasms (MPN)

Dr. Zeidner's research interests include discovering innovative methods to improve outcomes, drug discovery and development, and designing clinical trials in acute myeloid leukemia (AML) myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs).

He leads the Leukemia Clinical Trials Research Protocol Office Disease (POD) Group where we have a multitude of cutting-edge clinical trials for acute leukemia, MDS, and MPNs. Dr. Zeidner's the Principal Investigator of industry-sponsored, investigator-initiated, and academic collaborative clinical trials evaluating novel agents in MDS and AML. His research focus encompasses drug development in two distinct pathways in AML: 1) cyclin-dependent kinase inhibitors, and 2) innovative immunotherapeutic strategies.

Practice Location: 
Lineberger Comprehensive Cancer Center
Chapel Hill , NC 27599 ,
Physician Status: 
  • accepting new patients